FindTrial
Sign In

mRNA-1647

BIOLOGICAL9 trials

Sponsors

ModernaTX, Inc.

Conditions

CytomegalovirusCytomegalovirus InfectionRespiratory Syncytial VirusSARS-CoV-2Seasonal Influenza

Phase 1

Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
CompletedNCT03382405
ModernaTX, Inc.Cytomegalovirus Infection
Start: 2017-11-13End: 2020-10-28Updated: 2021-01-15
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
CompletedNCT05105048
ModernaTX, Inc.Cytomegalovirus Infection
Start: 2021-11-08End: 2023-08-10Updated: 2023-09-11
A Study of Modified mRNA Vaccines in Healthy Adults
CompletedNCT05397223
ModernaTX, Inc.Cytomegalovirus, Respiratory Syncytial Virus, SARS-CoV-2 +1
Start: 2022-05-24End: 2026-02-27Updated: 2026-03-12
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
Active, not recruitingNCT05575492
ModernaTX, Inc.Cytomegalovirus
Start: 2022-11-07End: 2027-01-15Updated: 2025-12-15

Phase 2

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
CompletedNCT04232280
ModernaTX, Inc.Cytomegalovirus Infection
Start: 2020-01-09End: 2023-01-04Updated: 2024-01-03
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
CompletedNCT04975893
ModernaTX, Inc.Cytomegalovirus Infection
Start: 2021-06-18End: 2026-01-19Updated: 2026-02-02
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
RecruitingNCT05683457
ModernaTX, Inc.Cytomegalovirus Infection
Start: 2023-04-05End: 2026-08-01Target: 224Updated: 2026-03-16
A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
WithdrawnNCT06133010
ModernaTX, Inc.Cytomegalovirus Infection
Start: 2024-02-08End: 2027-12-14Updated: 2024-03-15

Phase 3

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
TerminatedNCT05085366
ModernaTX, Inc.Cytomegalovirus Infection
Start: 2021-10-26End: 2025-11-04Updated: 2025-12-15

Related Papers

An mRNA influenza vaccine induces immunity comparable to an adjuvanted vaccine in a randomized trial.
2026-01-14
90. Interim Assessment of Safety and Immunogenicity From a Proof-of-Concept Phase 2 Trial of an mRNA-Based Cytomegalovirus Vaccine in Patients Who Have Undergone Allogeneic Hematopoietic Cell Transplantation
Open Forum Infectious Diseases2026-01-01
P-1454. mRNA-Based Respiratory Syncytial Virus Vaccine mRNA-1345 Induces Robust, Polyfunctional, and Durable CD4+ and CD8+ T Cell Responses with Similar Features in Adults Across Age Groups
Open Forum Infectious Diseases2026-01-01
P-1453. Characterization of longitudinal humoral and cellular immunogenicity following 2 or 3 doses of an mRNA-based cytomegalovirus vaccine in healthy adults
Open Forum Infectious Diseases2026-01-01
P-1452. A Seasonal Influenza Hemagglutinin mRNA-Based Vaccine Induces Humoral and Cellular Immunity Comparable to an Adjuvanted Inactivated Influenza Virus Vaccine
Open Forum Infectious Diseases2026-01-01
mRNA-1010 influenza vaccine elicits distinct and enhanced humoral immunity compared to adjuvanted inactivated vaccines.
2025-12-15
An mRNA-based cytomegalovirus vaccine induces robust T-cell immune responses in cytomegalovirus-seropositive adults who have undergone allogeneic hematopoietic cell transplantation
Blood2025-11-03
Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study
Frontiers in Immunology2025-04-105 citations
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.
2024-08-0148 citations
Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults
Journal of Virology2024-03-2518 citations
Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial
The Journal of Infectious Diseases2024-03-1345 citations
Update on Vaccines in Antenatal Care
The Pediatric Infectious Disease Journal2023-12-271 citations
Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.
2023-12-0540 citations
2892. Safety and Immunogenicity of mRNA-1647, an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results of a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial
Open Forum Infectious Diseases2023-11-2721 citations
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis.
2023-06-1984 citations
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
2022-12-0532 citations
112. Interim Results From a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial of an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults
Open Forum Infectious Diseases2022-12-0110 citations
Congenital Infections: Priorities and Possibilities for Resource-limited Settings
The Pediatric Infectious Disease Journal2022-09-121 citations